Courtney M. Tate
YOU?
Author Swipe
View article: Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
p38α mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38α MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and …
View article: Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 90K, shRNA silencing of p38a MAPK in U-87MG glioma (Westerns and xenograft tumor growth data).
View article: Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 43K, Effect of LY2228820 on MK2 phosphorylation in mouse peripheral blood mononuclear cells (PBMC) and from patients with multiple myeloma.
View article: Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 90K, shRNA silencing of p38a MAPK in U-87MG glioma (Westerns and xenograft tumor growth data).
View article: Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 43K, Effect of LY2228820 on MK2 phosphorylation in mouse peripheral blood mononuclear cells (PBMC) and from patients with multiple myeloma.
View article: Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 86K, Supplemental Table 1. Kinases where LY2228820 shows >1000-fold selectivity in vitro (p38 MAPK vs. other kinase).
View article: Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
p38α mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38α MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and …
View article: Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 86K, Supplemental Table 1. Kinases where LY2228820 shows >1000-fold selectivity in vitro (p38 MAPK vs. other kinase).
View article: Supplementary Table S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Summary of changes in immune cell subsets from baseline to Cycle 1 Day 8 after LY3022855 treatment.
View article: Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Time plots of circulating levels of interleukin-34
View article: Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Dose selection details, T cell activation/exhaustion flow assay and multiplex cytokine measurements.
View article: Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Best overall response by RECIST 1.1 and PCWG2 for bone.
View article: Supplementary Table S4 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S4 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Relationship between confounding factors and response (RECIST).
View article: Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Summary of noncompartmental pharmacokinetic parameters following intravenous infusion of LY3022855.
View article: Supplementary Figure S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Figure S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Change in tumor biomarkers by response (RECIST) during LY3022855 treatment.
View article: Supplementary Figure S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Figure S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Change in tumor biomarkers by response (RECIST) during LY3022855 treatment.
View article: Supplementary Table S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Summary of changes in immune cell subsets from baseline to Cycle 1 Day 8 after LY3022855 treatment.
View article: Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Summary of noncompartmental pharmacokinetic parameters following intravenous infusion of LY3022855.
View article: Supplementary Figure S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Figure S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Assessment of tumor associated macrophage depletion using macrophage gene signature. The downward trend (pre vs post, indicating depletion of TAMs) of the gene signature did not appear pronounced in any of the patient samples except for pa…
View article: Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Best overall response by RECIST 1.1 and PCWG2 for bone.
View article: Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Purpose:Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocyte…
View article: Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Purpose:Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocyte…
View article: Supplementary Table S4 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S4 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Relationship between confounding factors and response (RECIST).
View article: Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Time plots of circulating levels of interleukin-34
View article: Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Dose selection details, T cell activation/exhaustion flow assay and multiplex cytokine measurements.
View article: Supplementary Figure S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Figure S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Assessment of tumor associated macrophage depletion using macrophage gene signature. The downward trend (pre vs post, indicating depletion of TAMs) of the gene signature did not appear pronounced in any of the patient samples except for pa…
View article: Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocyt…
View article: Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant
Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant Open
View article: Analysis of Pharmacists Ability to Counsel on Smoking Cessation Products
Analysis of Pharmacists Ability to Counsel on Smoking Cessation Products Open
Learning Objective: • Describe the need for continuing education (CE) for community pharmacists regarding available smoking cessation therapy and appropriate counseling for those ready to quit. Background: • Approximately 1 in 5 adults smo…
View article: A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology
A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology Open
Bone morphogenetic proteins (BMPs), members of the TGF-β superfamily, have numerous biological activities including control of growth, differentiation, and vascular development. Using an in vitro co-culture endothelial cord formation assay…